Radretumab
Radretumab
Radretumab (pronounced rad-re-tu-mab) is a monoclonal antibody used in the treatment of certain types of cancer. It is a type of radioimmunotherapy.
Etymology
The name "Radretumab" is derived from the Latin "rad" meaning "ray", referring to its radioactive properties, and "retumab", a common suffix for monoclonal antibodies.
Usage
Radretumab is used in the treatment of solid tumors, particularly those that are resistant to other forms of treatment. It works by binding to a specific protein on the surface of cancer cells, allowing a radioactive substance to be delivered directly to the tumor.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Radioimmunotherapy: A type of therapy that uses radioactive substances in combination with antibodies to treat cancer.
- Solid tumor: An abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign (not cancer), or malignant (cancer). Different types of solid tumors are named for the type of cells that form them.
See Also
External links
- Medical encyclopedia article on Radretumab
- Wikipedia's article - Radretumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski